Santarus, Inc. (NASDAQ:SNTS)

dunloggin (67.29) Submitted: 10/18/2010 11:11:16 AM : Start Price: $3.12 SNTS Score: +41.24

Taking a flier on this one.

21popsontop (< 20) Submitted: 10/14/2010 1:31:12 AM : Start Price: $3.10 SNTS Score: +42.16

This longshot looks like a warrior on a bear hunt.

humbledutch (< 20) Submitted: 8/19/2010 3:44:40 PM : Start Price: $2.36 SNTS Score: +80.93

Good earnings, strong balance and generating cashflow

therock050383 (< 20) Submitted: 5/20/2010 12:42:24 PM : Start Price: $2.91 SNTS Score: +42.58

At this point, everyone is assuming the worst case scenario with generic Zegerid regarding Par Pharma, and this is priced into the stock....The company has over $1.50/share in cash alone....At current prices, the rest of the company flagship without the cash is priced at $72 million.....They will have $50 million in Glumetza sales this year, Merck just launched Zegerid OTC 1 1/2 months ago (in which SNTS will receive royalties moving forward), plus two late stage III drugs.....(All priced at $72 million), and they will still have $100 + million in Zegerid prescription sales this year........seems cheap.

graniteguys (43.31) Submitted: 5/19/2010 8:25:42 PM : Start Price: $2.96 SNTS Score: +40.73

call this a winner easily double

SmallPimpin (94.69) Submitted: 4/15/2010 4:50:22 PM : Start Price: $3.65 SNTS Score: +21.41

Mmm...pharmaceuticals...

markymark69 (< 20) Submitted: 3/13/2010 3:55:44 AM : Start Price: $4.68 SNTS Score: -13.36

Great cash flow. Almost no debt. Double digit royalties coming in this year in addition to potential cash payment $35mil from Merck. I'm riding this one out to $7/share

Brian7992 (< 20) Submitted: 8/11/2009 2:29:09 PM : Start Price: $3.12 SNTS Score: +19.97

Buy me now!

poppinkid (87.19) Submitted: 5/8/2008 9:12:28 PM : Start Price: $2.51 SNTS Score: +93.69

Highly underrated. GERD treatments are not that effective and LR PPI drugs don't provide immediate relief. Zegrid has a IR formulation that is significantly better than current prescriptions and OTC products. Hence, Schering and Glaxo's interest in co-promotion. This is a 14B market, and 5% of that market will make this an easy 4 bagger. The PAR case is causing hang over, but look for that to resolved and for profitability in 2009.

RRUI (< 20) Submitted: 3/5/2008 2:58:35 PM : Start Price: $2.09 SNTS Score: +128.33

SNTS has been hampered primarily by a patent challenge by Par Pharm. and the stock took a huge hit when this claim came out primarily for two reasons. 1) CEO had stopped giving guidance on a call a few days before and 2) market thought that perhaps the patent challenge would further hamper the cash flow situation at SNTS. Realistically, this suit will probably be settled or won by SNTS. SNTS should reach profitability in Q4, however, the market is overlooking the two major deals SNTS has signed with Glaxo (for foreign distribution) and Schering for OTC distribution. Both companies are comfortable with the patents as should you be. I look for a volatile rocky ride from here...but up it should be. Cheers.

meghanjack (93.86) Submitted: 6/29/2007 10:37:57 AM : Start Price: $5.56 SNTS Score: -6.01

good drug

murph74124 (38.74) Submitted: 4/6/2007 11:01:55 AM : Start Price: $7.50 SNTS Score: -33.45

addresses $billin market; secondary benefits re acid reflux;big co-marketing deals;faster PPI response;undiscovered by analysts

geeky1 (26.60) Submitted: 1/29/2007 8:24:54 PM : Start Price: $6.71 SNTS Score: -27.76

Hit bottom

Riccccardo4 (< 20) Submitted: 11/22/2006 3:43:28 PM : Start Price: $7.71 SNTS Score: -38.17

making great progress on their OTC version of Prilosec